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The use of neoadjuvant chemotherapy in operable breast cancer
may, at least in theory, eliminate early systemic micrometastases,
avoid rapid growth of metastases after treatment of the primary
site and hopefully prevent emergence of resistant clones (Bhalla
and Harris, 1998). The only demonstrated benefit in terms of treat-
ment effects is the achievement of tumour shrinkage, which allows
more conservative treatment in some patients (Fisher et al, 1997).
Several clinical trials have compared preoperative and postopera-
tive chemotherapy in operable breast cancer, but no significant
advantage in terms of long-term survival has been demonstrated to
date (Scholl et al, 1994; Semiglazov et al, 1994; Powles et al,
1995; Fisher et al, 1998; Mauriac et al, 1999). The response of
breast tumours to preoperative chemotherapy might also be
predictive of efficacy of therapy on distant disease and outcome. A
possible advantage of primary systemic treatment is to test in vivo
tumour response in order to modify treatment or introduce new
drugs postoperatively. Finally, the assessment of factors associated
with clinical and pathological response is important for prognosis.
The NSABP B-18 trial showed that neoadjuvant chemotherapy
was able to reduce the incidence of positive nodes (Fisher et al,
1997). The presence of axillary lymph-node metastases represents
the single most important prognostic factor for patients under-
going surgery for primary breast cancer (Haagensen, 1977;
Valagussa et al, 1978). The prognosis is also inversely related to
the number of involved nodes (Nemoto et al, 1980; Fisher et al,
1983; Carter et al, 1989). Since neoadjuvant chemotherapy
reduces node involvement, it could possibly modify the prognostic
value of this parameter.
At the Institut Curie, primary radiotherapy for operable breast
carcinoma, in order to allow conservative surgery, has been used
for decades. Since 1981, neoadjuvant chemotherapy has also been
used in large operable breast cancer, prior to local–regional treat-
ment. The aim of this retrospective study was to assess the prog-
nostic value of the persistence of positive axillary nodes after
preoperative chemotherapy either by itself or in combination with
other prognostic factors.
PATIENTS AND METHODS
Patient selection
The present study is a retrospective analysis of the Institut Curie
Breast Cancer database. The selection criteria were prior neoadju-
vant chemotherapy for operable T2 or T3, N0 or N1 tumours and
surgery with axillary dissection. Patients with metastatic, locally
advanced or inflammatory cancer were excluded, as were patients
with bilateral tumours, prior cancer and male patients. Prognostic
factors were assessed in patients with a follow-up greater than 5
years and for whom information was available about pathological
axillary-node involvement.
Between 1981 and 1992, 936 patients who received neoadju-
vant chemotherapy were registered and selected according to our
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criteria, except for axillary dissection. Response rates and survival
data were assessed in the total population, as a ‘reference group’.
Axillary dissection was performed in only 507 of these patients.
Radiotherapy was proposed as an alternative to surgery. Axillary
dissection was performed in only one half of the patients selected
in our retrospective study, because of various strategies for
local–regional treatment according to patient and/or physician
preference, controlled trial arm and tumour response. Radio-
therapy alone was predominantly performed in good responders to
chemotherapy and/or radiotherapy. In 19 patients, surgery with
axillary dissection was performed at the time of local relapse and
these patients were excluded from the analysis. Finally, 488
patients were fully eligible for analysis of the prognostic value of
persistent node involvement following primary chemotherapy.
Pathological diagnosis and histological grading was performed
in all patients on drill biopsy specimens. Steroid receptor levels
were assessed by quantitative radioimmunoassay. From 1986
onwards, the cellular S-phase fraction (SPF) was determined in
225 tumours (46%), according to previously described techniques
(Remvikos et al, 1993). The cut-off value was 5%, above which
the proliferative index was considered to be high.
Treatment modalities
All patients received a median of four (1–6) cycles of neoadjuvant
chemotherapy. From 1983 onwards, chemotherapy consisted of
FAC or FEC with adriamycin (doxorubicin) 25 mg m–2 day 1 and
day 8 or epirubicin 50 mg m–2 day 1, cyclophosphamide 500 mg
m–2 day 1 and day 8, 5-fluorouracil 500 mg m–2 day 1, day 3, day 5
and day 8. Fifty nine (12%) of the 488 patients did not receive
anthracyclines, but thiotepa at a dose of 10 mg m–2 day 1 and day
8, in one arm (CTF) of a randomized trial. Before 1983, i.e. for 32
patients (6.5%), chemotherapy consisted of M2AC with doxoru-
bicin 50 mg m–2 day 1, cyclophosphamide 500 mg m–2 day 1 and
methotrexate 25 mg m–2 day 2 and day 9. Chemotherapy was
administered intravenously at 28-day intervals or longer
depending on bone-marrow recovery. 278 (57%) of the 488
patients were included in three different prospective trials. The
data for the rest of the patients were also prospectively registered.
After neoadjuvant chemotherapy and before local-regional
treatment, response was assessed by clinical measurements of both
the primary tumour and the axillary nodes. Response was scored
according to the Eastern Cooperative Oncology Group (ECOG)
criteria (Oken et al, 1982). A pathological complete response was
characterized as pCR when there was no evidence of residual
invasive tumour in the breast or axillary lymph nodes.
Local–regional treatment consisted of surgery with axillary
dissection either alone or combined with radiotherapy.
Conservative breast treatment consisting of tumourectomy before
or following radiotherapy was performed in 236 patients (48.4%).
Mastectomy could not be avoided in 252 patients (51.6%) and was
associated with radiotherapy in 179 patients (71%). In 166 patients
(34%), radiotherapy to the breast was performed before surgery in
order to increase the chances of breast preservation. Radiotherapy
was delivered at a mean dosage of 54 Gy over 6 weeks to the
breast or chest wall and lymph-node areas. Patients with complete
or almost complete response received a radiation boost to the
tumour bed to achieve a total dose of 75–80 Gy.
In controlled trials, postoperative treatment was not planned. For
patients who were not included in controlled trials, adjuvant tamox-
ifen could be given according to the hormonal status of the tumour.
Statistical methods
Survival time and disease-free survival time were measured from
the date of diagnosis to the date of death or last follow-up.
Differences between treatment groups were analysed by Chi-
square tests for categorical variables and Student t-test for contin-
uous variables. The survival and response duration curves were
determined using a Kaplan – Meier product-limit method (Kaplan
and Meier, 1958; Mantel, 1966). Statistical significance between
treatment groups was assessed using the log-rank test.
Multivariate analysis was carried out to assess the relative influ-
ence of prognostic factors on disease-free survival and overall
survival, using the Cox proportional hazards model in a forward
stepwise procedure (Cox, 1972). Missing values (tumour grade,
receptor levels) were coded as separate variables (missing, not
missing) and were retained in the model. So the Cox models were
done on the whole sample. P values < 0.05 were considered as
significant. Statistical analyses were performed by BMDP soft-
ware (BMDP Statistical Software Inc, Los Angeles CA, USA).
Nodal extent was divided into 0, 1–3, 4–7, and ≥ 8 nodes in
order to increase the number of patients in the last group and to
permit comparison with a current French multicentric adjuvant
trial in poor prognostic breast cancer patients (PEGASE 01).
RESULTS
Patient characteristics
Median age was 47 years and 75% of patients were premenopausal
(Table 1). Median tumour size was 4.5 cm and 55% of patients had
clinical lymph-node involvement. The pathological and laboratory
characteristics of the tumours were as follows: 80% of tumours
were grade 2 or 3, 87% of tumours were ductal carcinomas, pro-
gesterone receptors (PR) were positive in 52% of patients and
oestrogen receptors (ER) were positive in 57% of patients, S phase
was greater than 5% in 41% of patients. Patients who had received
preoperative chemotherapy and radiotherapy had the same propor-
tion of nodal involvement as those treated with preoperative
chemotherapy only, particularly for women with ≥ 8 nodes
positive (6% vs 7.5%; ns).
Tumour response to neoadjuvant chemotherapy
Objective clinical response rates immediately prior to
local–regional therapy were 52% with only 7% complete
responses. Another 31% of patients achieved a minor response.
Only 2% of patients presented tumour progression (Table 2). One
patient was lost to follow-up before response assessment.
Mastectomy was avoided in 48% of the patients in favour of
lumpectomy together with radiotherapy. Conservative treatment
was performed in a total of 68.2% of the patients who achieved a
major response. Conversely, mastectomy was avoided in only 27%
of the patients who did not achieve an objective clinical response.
Pathological response was assessed and available in the 288
patients not irradiated prior to surgery. The pathological complete
response rate was 5% (14 patients) and was significantly corre-
lated with clinical response (P = 0.047). Only one patient classi-
fied as a non-clinical responder had a pathological CR. The
objective clinical response rate for the complete ‘reference group’(936 patients), which included the 488 patients analysed in the
present report, was 58.3% with 15.5% of complete clinical
responses. The proportion of conservative treatment in the entire
population was 71.6%.
Long-term outcome
Median follow-up was 7 years (85 months, range 7–181 months).
157 deaths, 61 local relapses, 191 distant metastases and 215
events have occurred to date. Overall 5-year and 10-year survival
rates were 76% (95% CI, 71.8–79.8) and 55% (95% CI,
48.3–60.8), respectively (Table 3). The impact of persistent
lymph-node involvement after neoadjuvant chemotherapy on
disease-free survival was strongly correlated with the number of
positive nodes on axillary dissection (Figure 1, Table 4). Only 15
patients had more than 10 involved nodes. The median disease-
free survival was not reached at a median follow-up of 7 years,
particularly in patients with no node involvement, who repre-
sented 46% of the total population. In contrast, the median
disease-free survival for patients with eight or more positive nodes
was only 20 months. The 10-year disease-free survival rate was
7% and a similar impact was observed on overall survival (Figure
2, Table 4). The 10-year disease-free survival rate for patients with
no node involvement was 64%. Median survival for patients with
eight or more positive nodes was 48 months and the 10-year
survival rate was 26%. The same analysis was performed in the
subgroup of 322 patients who had not received preoperative radio-
therapy. The results concerning the impact of persistent patholog-
ical node involvement on outcome did not significantly different
according to whether or not the patients had received preoperative
radiotherapy (Table 5).
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Table 1 Patient characteristics
Patient characteristics n (488)
Tumour size
T2 312 64%
T3 176 36%
Median (range) 4.5 cm (2–12 cm)
Clinical lymph-node status
N0–N1a 219 45%
N1b 269 55%
Age ≤ 40 years 107 21.9%
Median (range) 47 years (24–71 years)
Premenopausal status 363 74.8%
SBR Grade
I 85 20%
II 250 59%
III 88 21%
Histology
ductal 420 87%
lobular 32 6.6%
others 30 6.4%
missing 6 –
Pregesterone receptors
negative 202 47.6%
positive 222 52.4%
missing 64 –
Oestrogen receptors
negative 165 42.8%
positive 220 57.2%
missing 103 –
S phase
≤ 5% 132 58.6%
>5% 93 41.4%
missing 262 –
Table 2 Clinical response evaluated before local–regional treatment
n (487) Percentage 95% CI
Complete response 34 7.0% 4.7– 9.3
Partial response ≥ 50% 221 45.4% 41–49.8
Minor response < 50% 152 31.2% 27.1–35.3
Stabilization 70 14.4% 11.3–17.5
Progression 10 2.0% 0.8– 3.2
Table 3 Long-term survival
(n = 487) 3 years 95% CI 5 years 95% CI 10 years 95% CI
(%) (%) (%)
Overall survival 88.2 85.2–91.1 75.8 71.8–79.8 54.6 48.3–60.8
Local relapse-free survival 91.2 88.6–93.8 87.9 84.8–91.1 81.8 76.9–86.7
Metastasis-free survival 73.6 69.6–77.6 64.3 59.8–68.7 53.1 47.4–58.7
(median = 160 months)
Disease-free survival 70.4 66.3–74.6 59.6 55–64.1 47.6 41.9–53.2
(median = 99 months)
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Figure 1 Disease-free survival according to node involvement (n = 487)The 5-year and 10-year survival rates for the complete ‘refer-
ence group’ (936 patients) were 80.4% (95% CI, 77.8–83.1) and
59.7% (95% CI, 55.7–63.7), respectively, and the corresponding 5-
year and 10-year disease-free survival rates were 59.5% (95% CI,
56.4–62.6) and 45.8% (95% Cl, 42–49.6), respectively.
Univariate and multivariate analysis
On univariate analysis, pathological node status was found to be
correlated with both clinical lymph-node status before
chemotherapy and clinical response of the primary tumour
Nodal status after neoadjuvant chemotherapy in breast cancer 1483
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Table 4 Survival according to lymph-node status
DFS OS
Nodes Patients median 5 years 10 years median 5 years 10 years
(months) ± SD ± SD (months) ± SD ± SD
Total 487 (100%) 99 60 ± 2% 48 ± 3% not 76 ± 2% 55 ± 3%
reached
0 223 (45.8%) not 72 ± 3% 63 ± 4% not 83 ± 3% 64 ± 5%
reached reached
1–3 159 (32.6%) 85 58 ± 4% 42 ± 5% 125 76 ± 4% 55 ± 5%
4–7 72 (14.8%) 55 47 ± 6% 35 ± 7% 91 68 ± 6% 43 ± 8%
≥ 8 34 (7%) 20 15 ± 6% 7 ± 5% 48 44 ± 9% 26 ± 8%
Logrank test P < 0.0001 P < 0.0001
Table 5 Disease-free survival (DFS) and overall survival (OS) according to lymph-node status and
preoperative radiotherapy
Nodes 5-year DFS ± SD 5-year OS ± SD
woPRT PRT woPRT PRT
(n = 322) (n = 166) (n = 322) (n = 166)
0 76.9 ± 6.8% 60.1 ± 12.3% 86.5 ± 5.9% 75.4 ± 10.9%
1–3 61.8 ± 10.2% 52.1 ± 12.9% 83.1 ± 7.8% 66.6 ± 12.3%
4–7 49.1 ± 15.9% 44 ± 19.4% 63.9 ± 15.5% 53.1 ± 17.1%
≥ 8 12.5 ± 13.3% 20 ± 24.9% 54.2 ± 19.9% 20 ± 24.7%
woPRT = without preoperative radiotherapy; PRT = with preoperative radio therapy
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Figure 2 Overall survival according to node involvement (n = 487)
Table 6 Correlation of histological lymph-node status and other prognostic
factors (univariate analysis)
Patient characteristics n pN0 pN1 P
(n = 223) (n = 265)
Clinical TUICC
T2 312 47.4% 52.6%
T3 176 42.6% 57.4% ns
Clinical NUICC
N0 N1a 219 68.5% 31.5% < 0.0001
N1b 269 27.2% 72.8%
SBR Grade
I–II 335 46.3% 53.7%
III 88 43.2% 56.8% ns
unknown 65
Age
≤ 40 years 107 42.9% 57.1% ns
> 40 years 381 46.5% 53.5%
Histology
ductal 420 44.7% 55.3%
lobular 32 53.1% 46.9% ns
others 30 53.4% 46.6%
unknown 6
Oestrogen receptors
negative 165 49.7% 21.8% ns
positive 220 42.7% 20.5%
unknown 103
Progesterone receptors
negative 202 44.6% 55.4% ns
positive 222 43.7% 56.3%
unknown 64
S Phase
≤ 5% 132 49.2% 50.8%
> 5% 93 50.5% 49.5% ns
unknown 263
Objective clinical response
Yes 255 50.2% 49.8% 0.04
No 232 40.8% 59.2%
Preoperative radiotherapy
Yes 166 40.9% 59.1%
No 321 48.0% 52.0% ns1484 J-Y Pierga et al
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(Table 6). 27% of patients diagnosed to have positive nodes on
clinical examination prior to treatment were node-negative on
pathological examination after chemotherapy and surgery. Clinical
response was correlated with small tumour size, negative clinical
lymph-node status, absence of progesterone receptors and high S-
phase values (Table 7). Univariate analysis also showed that all of
the usual prognostic parameters assessed in this study were corre-
lated with disease-free survival and overall survival (Table 8). No
correlation was demonstrated between histological response and
survival, probably because pathological response was obtained in
only 5% of patients. In a multivariate model (Table 9), outcome
remained strongly correlated with pathological lymph-node status,
with a 4.3-fold increased relative risk of death for patients with
eight or more positive nodes. Tumour grade and hormonal receptor
status were also associated with survival and disease-free survival.
Young age was associated with a short disease-free survival.
Preoperative radiotherapy was performed predominantly in poor
responders to chemotherapy (72.7%) and therefore is associated to
a poorer outcome in the univariate analysis for survival. On the
multivariate analysis, the clinical response of the tumour was
found to be an independent prognostic value of survival and
preoperative radiotherapy had no more prognostic significance.
DISCUSSION
The increase in the number of positive nodes is almost linearly
correlated with a decline in survival and the potential to achieve
cure (Fisher et al, 1983). The prognostic value of persistent node
involvement following neoadjuvant chemotherapy for locally
advanced breast cancer has been evaluated in several studies
(McCready et al, 1989; Gardin et al, 1995; Machiavelli et al, 1998;
Kuerer et al, 1999a). Fewer reports have been published in oper-
able breast cancer. Ellis et al (1998) showed that clinical but not
pathological axillary-node status was a major predictor of outcome
following primary chemotherapy. Conversely, pathological nodal
status was reported by Bonadonna et al, 1998) and Cameron et al,
(1997) to be the major prognostic factor associated with clinical
response to treatment on multivariate analysis. In another smaller
series, it was the only prognostic factor identified by a multivariate
model (Botti et al, 1995). Data from the MD Anderson Hospital
reported similar 10-year survival rates for primary doxorubicin-
based chemotherapy. Women with stage III breast cancer had
survival rates of 65%, 44%, 32% and 9%, when zero, 1–3, 4–9,
and 10 nodes were still involved after chemotherapy, respectively
(Frye et al, 1995).
It could be argued that the prognostic significance of the number
of nodes still containing tumour after preoperative chemotherapy
might simply reflect the number of nodes involved at presentation.
However, in the NSABP B18 trial, a 37% increase in the incidence
of pathologically negative nodes was seen following preoperative
chemotherapy: 43% in the postoperative group compared to 59%
in the preoperative group (Fisher et al, 1997). This decrease in
pathological nodal involvement was equally distributed in all cate-
gories of node involvement (1–3, 4–9 or ≥ 10 positive nodes).
However, it is not possible to separately identify those patients in
whom all histologically involved nodes were cured by pre-
operative treatment. In our study, pathological nodal status was
significantly correlated with clinical response (P = 0.04). The
absence of involved nodes may therefore reflect drug sensitivity,
at least in some cases, and Cox multivariate analysis revealed
this factor to be a more sensitive marker than clinical tumour
response.
Clinical response was an independent prognostic factor for
survival in this study, as previously reported in other trials
performed both in our institution (Scholl et al 1995) and by others
(Cameron et al, 1997). In the present study, radiotherapy alone
with a radiation boost to the tumour bed was proposed as sole local
– regional treatment for very good responders. Consequently, no
information was available about pathological axillary lymph-node
status in these patients. Pathological tumour response has been
reported to be a more powerful prognostic factor than clinical
response in locally advanced breast cancer (Sataloff et al, 1995;
Kuerer et al, 1999b) and more recently in operable breast cancer.
The pathological complete response rate including pathological
lymph-node status was 9% in the NSABP-B18 trial (Fisher et al,
1998) and quite low in the Milan experience (3%) (Bonadonna
et al, 1998).
The persistence of nodal involvement after neo-adjuvant
therapy may represent the existence of persistent systemic
micrometastases which are ultimately responsible for the patient’s
demise. However, in the present study, one might expect that
patients also given loco–regional radiotherapy would have less
nodal involvement for the same degree of micrometastatic disease.
The systemic disease had been exposed to identical anti-cancer
therapy, but the local nodes would have received radiotherapy.
There is a trend to a worse survival for patients who received
preoperative radiotherapy for the same number of involved nodes.
However, statistical comparisons were not significant.
Table 7 Clinical response to chemotherapy (univariate analysis)
Characteristics Objective clinical No response P
response
TUICC
T2 61.4% (191/311) 38.6% (120/311)
T3 36.4% (64/176) 63.6% (112/176) < 0.001
Mean tumour size 4.6 ± 1.5 cm 5.3 ± 1.9 cm < 0.001a
NUICC
N0 N1a 57.3% (125/218) 42.7% (93/218)
N1b 48.3% (130/269) 51.7% (139/269) 0.05
SBR Grade
I–II 51.5% (172/334) 48.5% (162/334)
III 51.1% (45/88) 48.9% (43/88) ns
Age
≤ 40 years 52.3% (56/107) 47.7% (51/107)
> 40 years 52.4% (199/380) 47.6% (181/380) ns
Histology
ductal 52.8% (222/420) 47.2% (198/420)
lobular 45.1% (14/31) 54.9% (17/31)
50% (15/30) 50% (15/30) ns
Oestrogen receptors
negative 58.2% (96/165) 41.8% (69/165)
positive 49.3% (108/219) 50.7% (111/219) 0.08
Pregesterone receptors
negative 58.2% (117/201) 41.8% (84/201)
positive 46.4% (103/222) 53.6% (119/222) 0.01
Histological lymph-node
status
pN0 57.4% (128/223) 42.6% (95/223)
pN1 48.2% (127/265) 51.8% (138/265) 0.04
S Phase
≤ 5% 53.8% (71/132) 46.2% (61/132)
> 5% 67.8% (63/93) 32.2% (30/93) 0.03
Preoperative radiotherapy
Yes 27.7% (46/166) 72.7% (120/166)
No 65.1% (209/321) 34.9% (112) < 0.001
aStudent t-test.Nodal status after neoadjuvant chemotherapy in breast cancer 1485
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Prediction of response is important, as response to treatment
constitutes a major prognostic factor. In the present study, tumour
response was also related to tumour size and clinical tumour
shrinkage was more marked in smaller tumours, as also reported in
the Milan series (Bonadonna et al, 1998). The probability of axil-
lary lymph-node involvement has been reported to progressively
increase with increasing size of the tumour (Nemoto et al, 1980),
but this relation was not observed in our study, possibly because
only T2 and T3 tumours were analysed. In our experience, absent
progesterone receptor (PR) expression correlated favourably with
response to chemotherapy and unfavourably with survival.
Colleoni had previously reported this correlation in a series of 73
patients receiving neoadjuvant chemotherapy (Colleoni et al,
1999). MacGrogan detected significant chemosensitivity for ER-
negative tumours, but not for PR-negative tumours (MacGrogan et
al, 1996), whereas other authors failed to observe a correlation
between hormone-receptor expression and response to
chemotherapy (Jain et al, 1996; Makris et al, 1997). One hypoth-
esis could be that PR-negative tumours have high proliferation,
since less differentiated. Therefore they relapse more rapidly but
are equally more sensitive to chemotherapy. In more recent publi-
cations, patient selection according to biological predictive factors
for response, including high S phase and c-erbB-2 overexpression,
remains one of the most challenging issues in neoadjuvant
chemotherapy (Colleoni et al, 1999). S phase was available in only
a small fraction of the patients in this series. Nevertheless, high S
phase remained predictive of clinical response to neoadjuvant
chemotherapy on multivariate analysis as previously reported
(Remvikos et al, 1989). Pathological lymph-node involvement
may constitute a response criterion to determine the efficacy of
neoadjuvant chemotherapy. The correlation between the risk of
developing distant metastases and axillary content is consistent
with the hypothesis that axillary involvement is an index of the
capacity for tumour spread, but it is not the cause of dissemination
and may not be a predictive marker of response to treatment.
How can the efficacy of neoadjuvant chemotherapy be
increased? Complete clinical response rates of more than 60%
have been obtained following continuous infusion of 5-fluo-
rouracil associated with epirubicin and cisplatin (Smith et al,
1995). New drugs such as taxanes are currently under investiga-
tion in combination with anthracyclines as neoadjuvant treatment
in order to increase the pathological complete response rate (Costa
et al, 1999). The role of docetaxel is being investigated before or
after neoadjuvant chemotherapy in the current NSABP trial B27
(Mamounas, 1998). One of the secondary objectives of this trial is
to determine whether there might be a benefit from addition of
postoperative docetaxel chemotherapy, particularly in a sub-
group of patients such as those with residual positive nodes after a
Table 8 Disease-free survival (DFS) and overall survival (univariate analysis, n = 487)
DFS Logrank Overall survival Logrank
Characteristics n 5 years 10 years 5 years 10 years
(%) (%) (%) (%)
TUICC
T2 311 62.3 45.7 80.9 58.7
T3 176 54.9 49.1 P = 0.33 67.4 47.7 P = 0.01
NUICC
N0 N1a 218 71 59 83.2 63.3
N1b 269 51 39 P < 0.0001 70.1 49.1 P = 0.0012
Age
≤ 40 years 107 48 33 69 48
> 40 years 380 63 53 P = 0.0004 78 57 P = 0.06
SBR Grade
I–II 334 63 51 79.7 62
III 88 47.7 36 P = 0.001 56.5 35.9 P < 0.0001
Histology
Ductal 419 57.3 43.8 74.9 52.2
Lobular 32 75.8 55.6 ns 86.9 81.8 ns
Progesterone receptors
negative 201 52 39 66 41
positive 221 65 52 P = 0.005 83 65 P < 0.0001
Oestrogen receptors
negative 165 55 39 68 49
positive 218 64 47 ns 82 57 P = 0.02
Node involvement
pN0 223 71.8 63.3 83.1 64.4
pN 1–3 158 57.8 42.3 76.4 54.6
pN 4–7 72 47.5 34.5 68.1 43.1
pN ≥ 8 34 14.7 7.3 P < 0.0001 44.1 25.5 P < 0.0001
Clinical response
Yes 255 65.1 49.9 79.1 63.1
No 231 53.3 44.7 P = 0.04 72.1 47.2 P = 0.01
Preoperative radiotherapy
Yes 166 52.1 42.1 68.3 46.8
No 321 63.5 50.4 P = 0.04 79.9 59.9 P = 0.004
S Phase
≤ 5% 131 64.4 53.1 86.6 53.3
> 5% 93 51.1 24.8 P = 0.009 66.7 38.4 P = 0.0091486 J-Y Pierga et al
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preoperative combination of doxorubicin and cyclophosphamide.
The Aberdeen Breast Group has reported the activity of neo-adju-
vant docetaxel in patients with a poor response to anthracyline-
based chemotherapy (Hutcheon et al, 2000). Other second-line
treatments with or without high-dose chemotherapy might also be
considered in this population. Although recent studies have
reported disappointing results of chemotherapy intensification
(Pusztai and Hortobagyi, 1998), we feel that this strategy should
be investigated in patients with a high S phase.
Although preoperative tumour debulking is considered to be a
favourable prognostic factor, there is still a controversy concerning
the need to perform axillary dissection following an excellent clin-
ical response to systemic induction therapy. According to the
results of the NSABP B18 trial, 26% of clinically node-negative
patients with tumours ≤ 2 cm had pathologically positive nodes
after preoperative chemotherapy (Fisher et al, 1997). Although
preoperative therapy induces downstaging of axillary lymph-node
status, persistent pathological node involvement is an
unfavourable prognostic factor and does not argue in favour of
elimination of axillary lymph-node dissection. Since the use of
sentinel lymph-node biopsy as an alternative to axillary dissection
is becoming increasingly popular (Krag et al, 1998), this procedure
might be further investigated in patients receiving neoadjuvant
chemotherapy (Kuerer et al, 1999b). Patients with locally
advanced breast cancer and clinically positive axillary lymph
nodes following neoadjuvant chemotherapy will benefit from axil-
lary dissection to ensure local control (Kuerer et al, 1998).
However, the benefit of axillary dissection in patients with a clini-
cally negative axilla may be minimal and potentially harmful if the
axilla is irradiated, particularly as pathological staging does not
affect subsequent systemic treatment. A prospective randomized
trial of axillary dissection vs axillary radiotherapy in patients with
a clinically negative axilla following neoadjuvant chemotherapy
is presently underway to evaluate this hypothesis (Kuerer et al,
1998).
In conclusion, pathological lymph-node status after neoadjuvant
chemotherapy remains the major prognostic factor for survival in
large operable breast cancers. Axillary lymph-node dissection
should be considered to be an important component of combined
modality therapy for patients with large resectable breast
carcinoma, in order to identify subgroups of patients who may
benefit from alternative treatments in the adjuvant setting. New
strategies must be designed to increase the clinical response rate
and pathological tumour sterilization rate. The poor prognosis of
patients with extensive lymph-node involvement after preopera-
tive therapy justifies the development of alternative treatment
modalities.
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